ANDA 212504, held by PharmoBedient. Omega-3-ACID Ethyl Esters.
As of Nov 22, 2026, ANDA 212504 (Omega-3-ACID Ethyl Esters), held by PharmoBedient, was first approved by FDA on Aug 19, 2020, with 1 approved supplement and 0 published complete response letters.
Omega-3-acid ethyl esters is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (greater than or equal to 500 mg per dL) hypertriglyceridemia (HTG).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 19, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Omega-3-ACID Ethyl Esters1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS · capsule;oral | Omega-3-ACID Ethyl Esters | Rx |
| Jan 6, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 19, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters